Selick seems very excited about it. 85 % tumor shrinkage can indicate a " Breakthrough ".
Over 900 patients dosed with an excellent safety profile. Phase 1/2 trials can get the FDA nod with " out of the park " efficacy . ASCO will be exciting.
daay - where are you coming up with accelerated approval - I listened to the conference and it was not brought up once? That ship sailed when the OS data in the pancreatic trial was not robust enough. No doubt, ASCO could provide some dramatic data, but you can't get AA from a small, uncontrolled Phase 1/2a trial. Approval will come from STS in 2015, but by that time, the number of different cancer types and indications in the clinic will be double what it is now, and off-label use will dwarf the STS market.